Computer-aided detection of HER2 amplification status using FISH images: a preliminary study

The amplification status of human epidermal growth factor receptors 2 (HER2) genes is strongly associated with clinical outcome in patients with breast cancer. The American Society of Clinical Oncology Tumor Marker Guidelines Panel has recommended routine testing of HER2 status on all newly diagnosed metastatic breast cancers since 2001. Although fluorescent in situ hybridization (FISH) technology provides superior accuracy as compared with other approaches, current manual FISH analysis methods are somewhat subjective, tedious, and may introduce interreader variability. The goal of this preliminary study is to develop and test a computer-aided detection (CAD) scheme to assess HER2 status using FISH images. Forty FISH images were selected for this study from our genetic laboratory. The CAD scheme first applies an adaptive, iterative threshold method followed by a labeling algorithm to segment cells of possible interest. A set of classification rules is then used to identify analyzable interphase cells and discard nonanalyzable cells due to cell overlapping and/or other image staining debris (or artifacts). The scheme then maps the detected analyzable cells onto two other gray scale images corresponding to the red and green color of the original image followed by application of a raster scan and labeling algorithms to separately detect the HER-2/neu ("red") and CEP17 ("green") FISH signals. A simple distance based criterion is applied to detect and merge split FISH signals within each cell. The CAD scheme computes the ratio between independent "red" and "green" FISH signals of all analyzable cells identified on an image. If the ratio is ≥ 2.0, the FISH image is assumed to have been acquired from a HER2+ case; otherwise, the FISH image is assumed to have been acquired from HER2- case. When we applied the CAD scheme to the testing dataset, the average computed HER2 amplification ratios were 1.06±0.25 and 2.53±0.81 for HER2- and HER2+ samples, respectively. The results show that the CAD scheme has the ability to automatically detect HER2 status using FISH images. The success of CAD-guided FISH image analysis could result in a more objective, consistent, and efficient approach in determining HER2 status of breast cancers.

[1]  D. Hayes,et al.  When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D J O'Kane,et al.  A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. , 2000, The Journal of urology.

[3]  Bin Zheng,et al.  Automated detection and analysis of fluorescent in situ hybridization spots depicted in digital microscopic images of Pap-smear specimens. , 2009, Journal of biomedical optics.

[4]  T. Lörch,et al.  Automated fluorescent in situ hybridization (FISH) analysis of t(9;22)(q34;q11) in interphase nuclei , 2006, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[5]  J. Klijanienko,et al.  Detection and quantitation by fluorescence in situ hybridization (FISH) and image analysis of HER‐2/neu gene amplification in breast cancer fine‐needle samples , 1999, Cancer.

[6]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Dowsett,et al.  Current Perspectives on HER2 Testing: A Review of National Testing Guidelines , 2003, Modern Pathology.

[8]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[9]  Sunil R Lakhani,et al.  The pathology of familial breast cancer: Immunohistochemistry and molecular analysis , 1999, Breast Cancer Research.

[10]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[11]  David Gur,et al.  An ellipse-fitting based method for efficient registration of breast masses on two mammographic views. , 2008, Medical physics.

[12]  K. Shen,et al.  Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer , 2008 .

[13]  J. R. Reeves,et al.  Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.

[14]  Ioannis Pitas,et al.  Automated evaluation of her-2/neu status in breast tissue from fluorescent in situ hybridization images , 2005, IEEE Transactions on Image Processing.

[15]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[16]  Greg Yothers,et al.  Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. , 2002, Journal of the National Cancer Institute.

[17]  N. Personeni,et al.  HER‐2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma , 2003, Cancer.

[18]  L. Huo HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial , 2007 .

[19]  A. Zinsmeister,et al.  Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. , 1998, Blood.

[20]  R. Bast,et al.  2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G Konecny,et al.  The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. , 2000, Cancer treatment and research.

[22]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.